Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162677
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nayagam, Shevanthi | - |
dc.contributor.author | Chan, Polin | - |
dc.contributor.author | Zhao, Kun | - |
dc.contributor.author | Sicuri, Elisa | - |
dc.contributor.author | Wang, Xiaochun | - |
dc.contributor.author | Jia, Jidong | - |
dc.contributor.author | Wei, Lai | - |
dc.contributor.author | Walsh, Nick | - |
dc.contributor.author | Rodewald, Lance E. | - |
dc.contributor.author | Zhang, Guomin | - |
dc.contributor.author | Ailing, Wang | - |
dc.contributor.author | Zhang, Lan | - |
dc.contributor.author | Chang, Joo H. | - |
dc.contributor.author | Hou, WeiWei | - |
dc.contributor.author | Qiu, Yingpeng | - |
dc.contributor.author | Sui, Binyan | - |
dc.contributor.author | Xiao, Yue | - |
dc.contributor.author | Zhuang, Hui | - |
dc.contributor.author | Thursz, M.R. | - |
dc.contributor.author | Scano, Fabio | - |
dc.contributor.author | Low-Beer, Daniel | - |
dc.contributor.author | Schwartländer, Bernhard | - |
dc.contributor.author | Wang, Yu | - |
dc.contributor.author | Hallett, Timothy B. | - |
dc.date.accessioned | 2020-05-27T16:57:50Z | - |
dc.date.available | 2020-05-27T16:57:50Z | - |
dc.date.issued | 2020-04-07 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | http://hdl.handle.net/2445/162677 | - |
dc.description.abstract | BACKGROUND content: In 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world's population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of HBV interventions. METHODS content: A dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal perspective, incorporating costs of management of end-stage liver disease and lost productivity costs. RESULTS content: Despite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions is likely to have a positive return on investment to society of US$1.57 per US dollar invested. CONCLUSIONS content: Increases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-world example of how applied modeling can support national dialog and inform policy planning. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1093/cid/ciaa134 | - |
dc.relation.ispartof | Clinical Infectious Diseases , 2020 , vol. , num. , p. 0 | - |
dc.relation.uri | http://dx.doi.org/10.1093/cid/ciaa134 | - |
dc.rights | cc-by (c) Nayagam et al. , 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Hepatitis B | - |
dc.subject.classification | Xina | - |
dc.subject.other | Hepatitis B | - |
dc.subject.other | China | - |
dc.title | Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-05-22T18:01:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32255486 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Nayagam_S_Clin_Infect_Dis_2020.pdf | 345.54 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License